In addition, the expression of FMO2 in HER2 status, age status, PAM50 subtypes, and triple-negative breast cancer was also highly consistent with that in TCGA (all P < 0.001) (Supplementary Figure 1D–1I and Supplementary Table 1). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.